News Sentiment

DFTX sentiment intelligence

Definium Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 47.07 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+6.5% over one week, +90.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 6.5% Price confirming higher
Trend fit Trend active 90.2% over four weeks
Fair value 377.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 33
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 10
TradingView 8
Investing.com 6
marketscreener.com 5
simplywall.st 4
Sahm 2
Morningstar 1

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 17
Analyst action 7
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
Morningstar Direct company coverage

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

Definium Therapeutics has launched "Wired for Worry," an educational initiative for healthcare providers focusing on Generalized Anxiety Disorder (GAD). This program aims to deepen understanding of GAD's symptoms, lifelong impact, and neurobiology, as well as the importance of ea

Tone
Positive 72/100
Event
Market update
Published
16 Jul 2026 10:41
Source
Morningstar
marketscreener.com Direct company coverage

Definium Therapeutics, Inc. Announces Results from New Healthcare Claims Study of Treatment Patterns of Newly Diagnosed and Established Gad Patients, Including Pharmacotherapy Use, Discontinuation, Switching and Treatment Progression

Definium Therapeutics, Inc. announced results from a new healthcare claims study revealing significant unmet needs in Generalized Anxiety Disorder (GAD) treatment. The study, published in CNS Spectrums, highlights frequent discontinuation, switching, and prolonged gaps in care am

Tone
Positive 63/100
Event
Earnings
Published
14 Jul 2026 11:40
Source
marketscreener.com
Stock Titan Direct company coverage

More Than Half of Newly Diagnosed GAD Patients Stopped Therapy

A new healthcare claims study published in CNS Spectrums by Definium Therapeutics (DFTX) reveals that 55% of newly diagnosed Generalized Anxiety Disorder (GAD) patients discontinued their initial pharmacotherapy. The study highlights significant unmet needs in GAD treatment, with

Tone
Positive 65/100
Event
Market update
Published
14 Jul 2026 10:40
Source
Stock Titan
Sahm Direct company coverage

Definium Therapeutics (DFTX) Following Russell Index Removal And The Fair Value Debate

Definium Therapeutics (DFTX) is gaining attention after its removal from Russell indexes, with its stock showing significant recent momentum. While one analyst narrative suggests the stock is overvalued at $44.33 with a fair value of $35.23, based on its clinical pipeline and fut

Tone
Neutral 50/100
Event
Analyst action
Published
09 Jul 2026 02:40
Source
Sahm
Moomoo Direct company coverage

Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $60

Stifel has reiterated its Buy rating on Definium Therapeutics (DFTX.US) and increased the target price to $60. This continued positive outlook from Stifel suggests confidence in the company's future performance and valuation. The raised target price indicates an expectation of si

Tone
Positive 73/100
Event
Analyst action
Published
09 Jul 2026 02:09
Source
Moomoo
Quartr Direct company coverage

Definium Therapeutics Inc (DFTX) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Definium Therapeutics Inc. presented at the Canaccord Genuity 44th Annual Growth Conference, detailing clinical development for MM120 and MM402. MM120 is advancing to Phase III trials for GAD and MDD, demonstrating durable effects from a single dose, while MM402 is in Phase I for

Tone
Positive 71/100
Event
Market update
Published
09 Jul 2026 02:09
Source
Quartr
Investing.com Direct company coverage

Stifel raises Definium Therapeutics price target on MDD data

Stifel increased its price target for Definium Therapeutics (NASDAQ:DFTX) to $60 from $30, maintaining a Buy rating after strong MDD data for DT120. The firm believes the data significantly de-risks the program and could lead to peak revenues exceeding $4 billion. Definium Therap

Tone
Positive 72/100
Event
Analyst action
Published
07 Jul 2026 22:13
Source
Investing.com
Business Wire Direct company coverage

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. announced the issuance of inducement grants to eight new non-executive employees. These grants consist of options to purchase an aggregate of 169,740 common shares, vesting over four years. The grants were approved by the company's Compensation Committ

Tone
Positive 62/100
Event
Market update
Published
06 Jul 2026 20:10
Source
Business Wire
TradingView Direct company coverage

Enterprise value to EBITDA forward of Definium Therapeutics, Inc. – NASDAQ:DFTX

This article provides financial data for Definium Therapeutics, Inc. (NASDAQ: DFTX), specifically focusing on its Enterprise Value to EBITDA forward metric. The content highlights the company's financial overview on TradingView, indicating that the market is closed with no trades

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 12:42
Source
TradingView
Finviz Direct company coverage

DFTX - Definium Therapeutics Inc Volatility & Greeks

This article provides a detailed financial overview of Definium Therapeutics Inc (DFTX), covering its stock performance, key financial metrics, volatility, and various Greek parameters relevant for options trading. It includes data such as market capitalization, income, sales, EP

Tone
Positive 65/100
Event
Market update
Published
02 Jul 2026 15:39
Source
Finviz
Reuters Direct company coverage

LSD therapy biotech Definium fends off trade-secret lawsuit

A federal judge in Delaware dismissed a trade-secret lawsuit against psychedelic therapy developer Definium Therapeutics, filed by clinical-trial provider Signant Health. The judge ruled that Signant's complaint failed to adequately identify protectable trade secrets. Definium, f

Tone
Neutral 50/100
Event
Regulatory and legal
Published
01 Jul 2026 17:09
Source
Reuters
Global Legal Chronicle Direct company coverage

Definium Therapeutics Completes $805 Million Upsized Public Offering

Definium Therapeutics, Inc., formerly Mind Medicine, a late-stage clinical biopharmaceutical company, has successfully completed an upsized $805 million public offering. Hogan Lovells advised Definium Therapeutics on this transaction. Access to the full details of the offering re

Tone
Positive 68/100
Event
Market update
Published
01 Jul 2026 00:39
Source
Global Legal Chronicle
The Globe and Mail Direct company coverage

Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Definium Therapeutics (DFTX)

Two healthcare stocks, Crinetics Pharmaceuticals (CRNX) and Definium Therapeutics (DFTX), have received bullish ratings from analysts. Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating for Crinetics Pharmaceuticals with an $83.00 price target, while Paul Matteis a

Tone
Positive 71/100
Event
Analyst action
Published
30 Jun 2026 22:41
Source
The Globe and Mail
Insider Monkey Direct company coverage

Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?

Definium Therapeutics, Inc. (NASDAQ:DFTX) recently received a positive update from Robert W. Baird analyst Christopher Chen, who increased the company's price target to $57 from $37, maintaining an Outperform rating following positive Emerge trial results. The biopharmaceutical c

Tone
Positive 72/100
Event
Analyst action
Published
30 Jun 2026 13:39
Source
Insider Monkey
Investing.com Direct company coverage

Canaccord cuts Definium Therapeutics stock price target on share count

Canaccord has lowered its price target for Definium Therapeutics (NASDAQ: DFTX) to $58 from $60, while maintaining a Buy rating. This adjustment follows a recent share offering by the company, increasing the share count, but the firm's unadjusted sales projections for its drug ca

Tone
Neutral 50/100
Event
Analyst action
Published
30 Jun 2026 11:39
Source
Investing.com
marketscreener.com Direct company coverage

Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell 3000 Value Benchmark

Definium Therapeutics, Inc. (NasdaqGS:DFTX) has been removed from the Russell 3000 Value Benchmark. The company, known for developing therapeutics for psychiatric and neurological disorders, is currently trading at $46.55, up 3.56% after hours. Recent news includes its entry into

Tone
Negative 40/100
Event
Market update
Published
29 Jun 2026 12:55
Source
marketscreener.com
marketscreener.com Direct company coverage

Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell Small Cap Comp Value Benchmark

Definium Therapeutics, Inc. (NasdaqGS:DFTX) has been removed from the Russell Small Cap Comp Value Benchmark. The company, formerly known as Mind Medicine (MindMed) Inc., is focused on developing therapeutics for psychiatric and neurological disorders, with its lead candidate, DT

Tone
Negative 35/100
Event
Market update
Published
29 Jun 2026 10:10
Source
marketscreener.com
marketscreener.com Direct company coverage

Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell 3000E Growth Benchmark

Definium Therapeutics, Inc. (NasdaqGS:DFTX) has been removed from the Russell 3000E Growth Benchmark. Despite this change, the company continues to advance its pipeline of therapeutics for psychiatric and neurological disorders, including DT120 ODT, which has received FDA Breakth

Tone
Negative 32/100
Event
Market update
Published
29 Jun 2026 08:41
Source
marketscreener.com
marketscreener.com Direct company coverage

Definium Therapeutics, Inc.(NasdaqGS: DFTX) dropped from Russell Microcap Index

Definium Therapeutics, Inc. (NasdaqGS: DFTX) has been removed from the Russell Microcap Index. The company is focused on developing therapeutics for psychiatric and neurological disorders, with a lead candidate, DT120 ODT, targeting generalized anxiety disorder (GAD) and major de

Tone
Negative 34/100
Event
Market update
Published
29 Jun 2026 05:41
Source
marketscreener.com
TradingView Direct company coverage

Price to sales forward of Definium Therapeutics, Inc. – NASDAQ:DFTX

This article displays a financial metric, the "Price to sales forward," for Definium Therapeutics, Inc. (NASDAQ: DFTX). It presents this data within the TradingView platform's market analysis section, indicating that it is a snapshot of financial performance for the company. The

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 03:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Definium Therapeutics, Inc. – NASDAQ:DFTX

This article provides financial information for Definium Therapeutics, Inc. (NASDAQ: DFTX), specifically focusing on its forward price-to-earnings ratio. It is presented in a data-centric format from TradingView, indicating market status, and links to various financial data sourc

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 17:11
Source
TradingView
TradingView Direct company coverage

Price to book forward of Definium Therapeutics, Inc. – HAM:MMQ0

This article provides the "Price to book forward" for Definium Therapeutics, Inc. (HAM:MMQ0), a pharmaceutical company listed on the Hamburg Stock Exchange. The current market status is closed with no trades. The information is presented within the TradingView platform, which off

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 16:11
Source
TradingView
TradingView Direct company coverage

Price to earnings ratio of Definium Therapeutics, Inc. – HAM:MMQ0

The article focuses on the price-to-earnings ratio of Definium Therapeutics, Inc. (HAM:MMQ0), a company listed on the Hamburg Stock Exchange. It provides financial overview, but no actual ratio is displayed, indicating that the market is closed with no trades.

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 00:40
Source
TradingView